COVID-19 vaccine
vaccine against SARS-CoV-2 coronavirus
A COVID‑19 vaccine is designed to induce immunity against SARS-CoV-2, the virus responsible for coronavirus disease 2019 (COVID-19). COVID-19 vaccines help reduce the risk of severe illness, hospitalization and death from the virus.
COVID‑19 vaccines were developed at an unprecedented pace to tackle the COVID-19 pandemic, with the first clinical trials beginning in March 2020. Before approval, vaccines underwent the standard three phases of clinical trials, although phases were conducted in parallel to accelerate development. Vaccines have been developed based on both classical technologies (using inactivated virus or protein subunit) and novel platforms (mRNA or viral vector-based).
Prior research on coronaviruses causing severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) accelerated the development of various vaccine platforms in early 2020. The 2023 Nobel Prize in Physiology or Medicine was awarded to Katalin Karikó and Drew Weissman for the development of effective mRNA vaccines against COVID‑19.
Major vaccines include the Pfizer–BioNTech mRNA vaccine, Moderna mRNA vaccine, and the Novavax protein subunit vaccine. With the emergence of new SARS-CoV-2 variants, the original vaccines—particularly Pfizer–BioNTech and Moderna vaccines—have been updated. These "variant-adapted" vaccines are offered as booster doses.
This brief starts where responsible research should: with the source description of “COVID-19 vaccine” as vaccine against SARS-CoV-2 coronavirus. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the general reference register because the source frames it as vaccine against SARS-CoV-2 coronavirus. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Sep 13, 2026. The linked authority identifier is Q87719492. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2019, 2020 and 2023.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “COVID-19 vaccine”, its source revision and the description used here.
- Expand the search: follow COVID-19 vaccine primary sources, COVID-19 vaccine archive and COVID-19 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “COVID-19 vaccine”?
- Which institution is responsible for the underlying evidence?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “COVID-19 vaccine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.